$MGTA update from 2021 ASCO Annual Meeting

Before ASCO data was released today (see ASCO21 expectations post), MGTA-145 was positioned as a clear-cut superior alternative to existing mobilizing agents. It collected more cells, was higher quality, safer and more convenient.

After today’s data, MGTA-145 collects approximately the same number of cells as competitors, but still provides other benefi…